molecules of the month


oral, dual-selective αvβ6-αvβ1 integrin inhibitor

Ph. II for IPF and PSC

related to reported integrin inhibitors

Press release, January 22, 2023

Pliant Therapeutics, South San Francisco, CA

bexotegrast chemical structure oral, dual-selective αvβ6/αvβ1 integrin inhibitor - Pliant Therapeutics, South San Francisco, CA
8 mins read

A surprisingly safe and possibly efficacious dual-selective αvβ6-αvβ1 inhibitor, providing therapeutic entry to the notoriously challenging TGF-β pathway. Integrins are cell adhesion proteins that help cells bind to the extracellular matrix and have a range of signaling functions. The arginyl-glycinyl-aspartic acid (RGD) subfamily of αv integrins have been studied for decades in a variety of indications including cancer and idiopathic pulmonary fibrosis (IPF). Targeting αv integrins has been attractive yet challenging as they are upstream of transforming growth factor-β (TGF-β), and both small molecule and antibody-based integrin inhibitors have demonstrated preclinical toxicities in non-human primates, including cardiovascular toxicities and hyperplasia. TGF-β is an extensively studied target with established roles across therapeutic areas, but the systemic blockade of its pathway comes…

request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.

already a member? log in: